Cisbio Bioassays Selects CyBio Robotic Workstation
27 Jan 2009Cisbio Bioassays, a member of IBA group and a global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, announced at ALA in Palm Springs, CA that it has added CyBio’s robotic workstation to its laboratory for enhanced assay development services.
The combination of Cisbio’s expertise with CyBio’s flexible and reliable workstation will enable Cisbio to reinforce its service offering, which includes custom assay development for the creation and optimization of HTRF assays. HTRF is Cisbio’s highly sensitive, robust technology for the detection of molecular interactions that is widely used by the pharmaceutical industry for the high throughput screening stage of drug development. The CyBio workstation, a customized, modular, multi-functional automation platform for high throughput applications, allows for efficient testing under different assay conditions and applied research using high-density plate formats including 384-w low volume and 1536-w, the standards in today’s high throughput screening industry.
“Services are an integral part of our business and we strive to optimize HTRF’s flexibility and miniaturization capabilities with state-of-the art equipment that is well-adapted to an assay development platform,” said François Degorce, director of marketing, Cisbio Bioassays. “We selected CyBio’s robotic workstation because of their reputation for supplying high-quality and precise dispensing materials, as well as their reactive customer service, a concept which Cisbio both understands and values.”
Each CyBio workstation is individually designed using CyBio equipment and integrated parts. Starting with a base module, the workstation is customized to meet specific process, throughput and capacity requirements. Its integrated components, such as pipettors, incubators, readers, dispensers and other automation modules, work together to automate an assay from set-up to data collection.